What if you could test for the virus that causes COVID-19 within minutes?

The iQ Group Global has announced a pilot study to develop a printable point-of-care SARS-CoV-2 antibody test for the COVID-19 disease that could produce results in real-time.

The pilot study involves the integration of the Biosensor Platform with a proprietary coating developed at the Wyss Institute for Biologically Inspired Engineering that can detect IgM and/or IgG antibodies, which indicate a person’s current or previous exposure to the SARS-CoV-2 virus and, thus, a potential infection with COVID-19.

Based on the data generated in this pilot study, further development could result in a chewing-gum-sized diagnostic ‘strip’ that can be used for COVID-19 testing at point of care, with the ability to be printed at scale at a low cost, and produce real-time results.

Dr George Syrmalis

Group CEO and Chairman, The iQ Group Global
“We know that accurate, real-time diagnostic tools are a future of global healthcare that we urgently need to accelerate into our current reality. Dependent on the outcomes of this research, we may be in a position to provide the global healthcare system with a point-of-care test capable of detecting SARS-CoV-2 antibodies, with the ability to provide results in minutes.”

The Biosensor

Platform

What if there was a way to get an accurate medical diagnosis with your doctor, without having to send your test to a laboratory?

The Biosensor platform is a printable organic thin-film transistor ‘strip’ being developed to put the power of accurate and timely diagnosis in the hands of patients and their primary health practitioners at point of care.

Using Organic Thin Film Transistor (OTFT) technology, the Biosensor platform is currently in development to test for up to 130 indications, ranging from glucose for diabetes management, to immunological conditions and communicable diseases.

Why is Point-of-Care Testing Important

During a Pandemic?

Why is Point-of-Care Testing Important During a Pandemic?

Never has the need for a fast, reliable and readily accessible diagnostic test been so crucial than right now, as countries across the globe gradually progress out of lockdown during the COVID-19 pandemic.

Point-of-Care Testing (PoCT) provides patients the ability to receive accurate and reliable testing results outside a clinical laboratory environment, at the site of patient care. Rather than having blood or respiratory samples sent to a laboratory for analysis with no clear indication of the waiting period to receive the outcome, PoCT can show this outcome in real-time.

The logistics of testing up to millions of people in a country is no small feat, and the ideal PoCT for COVID-19 would have both high sensitivity (detects a person with the disease as positive) and specificity (detects a person without the disease as negative) so there are very few or nil false positives or negatives.

The iQ Group Global: Creating the Medicines of

Tomorrow

What if we could create a world free of disease?

At The iQ Group Global, that’s all we think about.

The iQ Group Global is a group of companies that find, fund and develop bioscience discoveries to create life-changing medical innovations.

Recognised by The Australian Financial Review in the top five Most Innovative Healthcare Companies in 2019, The iQ Group Global’s flagship innovation is the Saliva Glucose Biosensor; the first non-invasive replacement for finger-prick blood glucose testing for diabetes management.


Contact